The study demonstrated for the first time the existence of an IKZF1-CRLF2 pathway in high-risk ALL and suggested that targeting this pathway could be used as a therapeutic approach for high-risk B-ALL. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.